{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:01:09Z","timestamp":1786993269086,"version":"build-2736575974"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jpeds.2021.06.033","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:02:11Z","timestamp":1624924931000},"page":"13-20.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Advances in the Therapy of Spinal Muscular Atrophy"],"prefix":"10.1016","volume":"236","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-7861","authenticated-orcid":false,"given":"Jenna","family":"Klotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Tesi Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9322-0608","authenticated-orcid":false,"given":"Sally","family":"Dunaway Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MyMy","family":"Buu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-9529","authenticated-orcid":false,"given":"John W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2021.06.033_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s12035-013-8399-5","article-title":"Spinal muscular atrophy and the antiapoptotic role of survival of motor neuron (SMN) protein","volume":"47","author":"Anderton","year":"2013","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib4","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ana.25101","article-title":"Natural history of infantile-onset spinal muscular atrophy","volume":"82","author":"Kolb","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","article-title":"Gain and loss of abilities in type II SMA: a 12-month natural history study","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2021.06.033_bib6","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.1212\/WNL.0000000000008166","article-title":"Long-term progression in type II spinal muscular atrophy: a retrospective observational study","volume":"93","author":"Mercuri","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.06.033_bib7","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1212\/WNL.0000000000011051","article-title":"Respiratory trajectories in type 2 and 3 spinal muscular atrophy in the iSMAC cohort study","volume":"96","author":"Trucco","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.06.033_bib8","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","article-title":"A natural history study of late onset spinal muscular atrophy types 3b and 4","volume":"255","author":"Piepers","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib10","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2021.06.033_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jpeds.2021.06.033_bib12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.06.033_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.06.033_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.nmd.2018.05.010","article-title":"Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function","volume":"28","author":"Pane","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2021.06.033_bib15","doi-asserted-by":"crossref","unstructured":"Darras BT, Masson R, Mazurkiewicz-Beldzinska M, Rose K, Xiong H, Zanoteli E, et\u00a0al. FIREFISH part 2: 24-month efficacy and safety of risdiplam in infants with type 1 spinal muscular atrophy (SMA). American Academy of Neurology 2021 Virtual Annual Meeting; April 17-22,\u00a02021.","DOI":"10.1055\/s-0041-1739636"},{"key":"10.1016\/j.jpeds.2021.06.033_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jocn.2019.12.056","article-title":"Transforaminal lumbar puncture for intrathecal access: case series with literature review and comparison to other techniques","volume":"72","author":"Velayudhan","year":"2020","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jpeds.2021.06.033_bib17","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1097\/BPO.0000000000001247","article-title":"Preliminary safety and tolerability of a novel subcutaneous intrathecal catheter system for repeated outpatient dosing of nusinersen to children and adults with spinal muscular atrophy","volume":"38","author":"Strauss","year":"2018","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.jpeds.2021.06.033_bib18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0040-1715481","article-title":"Multicenter experience with nusinersen application via an intrathecal port and catheter system in spinal muscular atrophy","volume":"51","author":"Flotats-Bastardas","year":"2020","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.jpeds.2021.06.033_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/NEN.0b013e3181a10ea1","article-title":"The developmental pattern of myotubes in spinal muscular atrophy indicates prenatal delay of muscle maturation","volume":"68","author":"Martinez-Hernandez","year":"2009","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yexcr.2005.08.019","article-title":"Hypomorphic Smn knockdown C2C12 myoblasts reveal intrinsic defects in myoblast fusion and myotube morphology","volume":"311","author":"Shafey","year":"2005","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jpeds.2021.06.033_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ana.25930","article-title":"Yeo and Darras: extraneuronal phenotypes of spinal muscular atrophy","volume":"89","author":"Yeo","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib23","author":"Risdiplam","year":"2020","journal-title":"drug label"},{"key":"10.1016\/j.jpeds.2021.06.033_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/acn3.51239","article-title":"Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy","volume":"8","author":"Sergott","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.06.033_bib26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type 1","volume":"225","author":"Feldman","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.06.033_bib27","series-title":"Letter to the MTM disease community","year":"2020"},{"key":"10.1016\/j.jpeds.2021.06.033_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.legalmed.2019.04.005","article-title":"An autopsy case of peliosis hepatis with X-linked myotubular myopathy","volume":"38","author":"Funayama","year":"2019","journal-title":"Leg Med (Tokyo)"},{"key":"10.1016\/j.jpeds.2021.06.033_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jpeds.2020.11.054","article-title":"Thrombotic microangiopathy following onasemnogene abeparvovec for spinal muscular atrophy: a case series","volume":"231","author":"Chand","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.06.033_bib30","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JND-190468","article-title":"Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2","volume":"7","author":"Glascock","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.jpeds.2021.06.033_bib31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1212\/WNL.0000000000008207","article-title":"Combination therapy with nusinersen and AVXS-101 in SMA type 1","volume":"93","author":"Lee","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.06.033_bib32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/mus.27034","article-title":"Combination molecular therapies for type 1 spinal muscular atrophy","volume":"62","author":"Harada","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2021.06.033_bib33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1517\/14712598.2015.1035645","article-title":"Strategies to circumvent humoral immunity to adeno-associated viral vectors","volume":"15","author":"Tse","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jpeds.2021.06.033_bib34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10238-019-00557-8","article-title":"Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies","volume":"19","author":"Lotfinia","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.jpeds.2021.06.033_bib35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jmg.2008.057950","article-title":"Congenital heart disease is a feature of severe infantile spinal muscular atrophy","volume":"45","author":"Rudnik-Schoneborn","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.jpeds.2021.06.033_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13023-017-0613-5","article-title":"Cardiac pathology in spinal muscular atrophy: a systematic review","volume":"12","author":"Wijngaarde","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2021.06.033_bib37","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/PHM.0b013e31804b1d66","article-title":"Medical considerations of long-term survival of Werdnig-Hoffmann disease","volume":"86","author":"Bach","year":"2007","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.jpeds.2021.06.033_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1055\/s-0034-1395348","article-title":"Cardiac function in types II and III spinal muscular atrophy: should we change standards of care?","volume":"46","author":"Bianco","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.jpeds.2021.06.033_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2021.06.033_bib40","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","article-title":"Observational study of spinal muscular atrophy type I and implications for clinical trials","volume":"83","author":"Finkel","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.06.033_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ppul.25140","article-title":"Nusinersen for spinal muscular atrophy type 1: Real-world respiratory experience","volume":"56","author":"Lavie","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib43","article-title":"Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single centre Australian experience","author":"Chen","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"10.1016\/j.jpeds.2021.06.033_bib44","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.06.033_bib45","doi-asserted-by":"crossref","first-page":"7S35","DOI":"10.1016\/S0929-693X(20)30275-X","article-title":"Functional and surgical treatments in patients with spinal muscular atrophy (SMA)","volume":"27","author":"Boulay","year":"2020","journal-title":"Arch Pediatr"},{"issue":"2 Meeting Abstract","key":"10.1016\/j.jpeds.2021.06.033_bib46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1542\/peds.144.2MA8.761","article-title":"Short-term clinical outcomes of hip reconstructive surgery in patients with spinal muscular atrophy","volume":"144","author":"Larson JS","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2021.06.033_bib47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","article-title":"Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care","volume":"28","author":"Mercuri","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2021.06.033_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/OGX.0000000000000491","article-title":"What's new in prenatal genetics? A review of current recommendations and guidelines","volume":"72","author":"Post","year":"2017","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.jpeds.2021.06.033_bib49","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/s41431-019-0415-4","article-title":"Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors","volume":"27","author":"Serra-Juhe","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jpeds.2021.06.033_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.semperi.2015.03.006","article-title":"Newborn screening for spinal muscular atrophy: Anticipating an imminent need","volume":"39","author":"Phan","year":"2015","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib51","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.nmd.2012.09.006","article-title":"Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I","volume":"23","author":"Finkel","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.jpeds.2021.06.033_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.283","article-title":"Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study","volume":"3","author":"Kolb","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib53","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000001033","article-title":"Nusinersen treatment in adults with spinal muscular atrophy","author":"Duong","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.jpeds.2021.06.033_bib56","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mus.23233","article-title":"Electrical impedance myography in spinal muscular atrophy: a longitudinal study","volume":"45","author":"Rutkove","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2021.06.033_bib57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2015.08.1532","article-title":"Quantitative muscle ultrasound measures rapid declines over time in children with SMA type 1","volume":"358","author":"Ng","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jpeds.2021.06.033_bib58","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.0b013e3181eccf8f","article-title":"Assessing spinal muscular atrophy with quantitative ultrasound","volume":"75","author":"Wu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.06.033_bib59","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"Alves","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.06.033_bib60","doi-asserted-by":"crossref","first-page":"e0139950","DOI":"10.1371\/journal.pone.0139950","article-title":"Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls","volume":"10","author":"Czech","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jpeds.2021.06.033_bib61","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpeds.2021.06.033_bib62","doi-asserted-by":"crossref","first-page":"13859","DOI":"10.1038\/s41598-017-14313-z","article-title":"Survival motor neuron protein is released from cells in exosomes: a potential biomarker for spinal muscular atrophy","volume":"7","author":"Nash","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jpeds.2021.06.033_bib63","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/acn3.779","article-title":"Neurofilament as a potential biomarker for spinal muscular atrophy","volume":"6","author":"Darras","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.jpeds.2021.06.033_bib64","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1111\/jcmm.14939","article-title":"Nusinersen treatment and cerebrospinal fluid neurofilaments: an explorative study on spinal muscular atrophy type 3 patients","volume":"24","author":"Faravelli","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jpeds.2021.06.033_bib65","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mus.26823","article-title":"Evaluation of body composition as a potential biomarker in spinal muscular atrophy","volume":"61","author":"Baranello","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jpeds.2021.06.033_bib66","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.braindev.2021.03.006","article-title":"Phenotypes of SMA patients retaining SMN1 with intragenic mutation","volume":"43","author":"Wijaya","year":"2021","journal-title":"Brain Dev"},{"key":"10.1016\/j.jpeds.2021.06.033_bib67","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1212\/NXG.0000000000000505","article-title":"Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy","volume":"6","author":"Mendonca","year":"2020","journal-title":"Neurol Genet"},{"key":"10.1016\/j.jpeds.2021.06.033_bib68","doi-asserted-by":"crossref","first-page":"E1110","DOI":"10.1002\/humu.21173","article-title":"A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy","volume":"31","author":"Vezain","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jpeds.2021.06.033_bib69","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00439-019-01983-0","article-title":"Complete sequencing of the SMN2 gene in SMA patients detects SMN gene deletion junctions and variants in SMN2 that modify the SMA phenotype","volume":"138","author":"Ruhno","year":"2019","journal-title":"Hum Genet"},{"key":"10.1016\/j.jpeds.2021.06.033_bib70","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddx166","article-title":"A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy","volume":"26","author":"Wu","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpeds.2021.06.033_bib71","doi-asserted-by":"crossref","unstructured":"Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, et\u00a0al. Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study, Neurotherapeutics, 2021, [Epub ahead of print].","DOI":"10.1007\/s13311-021-01120-8"},{"key":"10.1016\/j.jpeds.2021.06.033_bib72","series-title":"Scholar Rock announces positive proof-of-concept data from TOPAZ phase 2 trial interim analysis of SRK-015 in Patients with type 2 and 3 spinal muscular atrophy","year":"2020"},{"key":"10.1016\/j.jpeds.2021.06.033_bib73","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"10.1016\/j.jpeds.2021.06.033_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030075","article-title":"The identification of novel biomarkers is required to improve adult SMA patient stratification, diagnosis and treatment","volume":"10","author":"Smeriglio","year":"2020","journal-title":"J Pers Med"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621005813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621005813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:12:12Z","timestamp":1758359532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347621005813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":74,"alternative-id":["S0022347621005813"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.06.033","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Therapy of Spinal Muscular Atrophy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}